<DOC>
	<DOCNO>NCT02089659</DOCNO>
	<brief_summary>This study investigate influence hepatic insufficiency pharmacokinetics ( PK ) doravirine ( MK-1439 ) . In Part 1 , PK doravirine participant moderate hepatic insufficiency compare healthy control subject match regard mean age weight . If clinically meaningful increase doravirine exposure observe participant moderate hepatic insufficiency Part 1 , study Part 2 evaluate PK doravirine participant mild hepatic insufficiency .</brief_summary>
	<brief_title>A Study Investigate Influence Hepatic Insufficiency Pharmacokinetics Doravirine ( MK-1439 ) ( MK-1439-019 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>Body Mass Index ( BMI ) 19 40 kg/m^2 Continuous nonsmoker moderate smoker &lt; 20 cigarette equivalent per day . Agrees consume &lt; =10 cigarettes equivalent per day time screen period sample collection . In good health clinically significant electrocardiogram abnormality Hepatic impairment participant : diagnosis chronic ( &gt; 6 month ) , stable hepatic insufficiency feature cirrhosis due etiology . Part 1 : score 7 9 ChildPugh scale . Part 2 : score 5 6 ChildPugh scale . Females childbearing potential : sexually inactive &gt; =14 day study drug administration throughout study , use 2 acceptable method barrier contraception screen 14 day study drug administration . Mentally legally incapacitate significant emotional problem time screen expect study History presence clinically significant medical psychiatric condition disease History presence drug abuse within past 2 year History presence hypersensitivity idiosyncratic reaction study drug relate compound Female participant pregnant lactate Positive result breath alcohol urine drug screen ( unless due prescription drug use approve investigator ) screen Positive HIV screen Unable refrain anticipates use drug know significant inhibitor inducer cytochrome oxidase CYP3A Pglycoprotein , medication substance discontinue least 14 day study drug administration throughout study . Donation &gt; 500 mL blood significant blood loss within 56 day study drug administration Plasma donation within 7 day study drug administration Dosed another clinical trial within 28 day study drug administration Healthy control participant : positive hepatitis B surface antigen ( HBsAg ) hepatitis C virus ( HCV ) screening ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>